2016
DOI: 10.1186/s40880-016-0086-2
|View full text |Cite
|
Sign up to set email alerts
|

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Abstract: BackgroundEpidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors of the response to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment in lung adenocarcinoma. However, whether patients carrying EGFR 19 del and L858R mutations exhibit different responsiveness to EGFR-TKIs and what are the potential mechanism for this difference remain controversial. This study aimed to investigate the clinical outco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

5
32
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 41 publications
(38 citation statements)
references
References 26 publications
5
32
1
Order By: Relevance
“…Additionally, advanced NSCLC patients with exon 19 mutations showed longer progression‐free survival (PFS), compared with patients with exon 21 mutations, when treated with EGFR‐TKI therapy . Similarly, studies by Yu et al showed that patients with EGFR exon 19 mutations exhibited greater PFS and higher ORR than patients with exon 21 mutations during EGFR‐TKI treatment . The above‐mentioned studies indicated that the identification of EGFR mutation subtypes is beneficial for the establishment of more accurate and personalized targeted clinical therapy plans for patients with NSCLC.…”
Section: Discussionsupporting
confidence: 90%
See 3 more Smart Citations
“…Additionally, advanced NSCLC patients with exon 19 mutations showed longer progression‐free survival (PFS), compared with patients with exon 21 mutations, when treated with EGFR‐TKI therapy . Similarly, studies by Yu et al showed that patients with EGFR exon 19 mutations exhibited greater PFS and higher ORR than patients with exon 21 mutations during EGFR‐TKI treatment . The above‐mentioned studies indicated that the identification of EGFR mutation subtypes is beneficial for the establishment of more accurate and personalized targeted clinical therapy plans for patients with NSCLC.…”
Section: Discussionsupporting
confidence: 90%
“…8 Similarly, studies by Yu et al showed that patients with EGFR exon 19 mutations exhibited greater PFS and higher ORR than patients with exon 21 mutations during EGFR-TKI treatment. 9 The above-mentioned studies indicated that the identification of EGFR mutation subtypes is beneficial for the establishment of more accurate and personalized targeted clinical therapy plans for patients with NSCLC. In lung cancer, the EGFR mutation rate is directly related to ethnicity.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Most EGFRm are strong predictors of response to tyrosine-kinase inhibitors (TKIs), with particular reference to the commonest E746-A750 deletion on exon 19 (ELREA) and L858R mutation in exon 21 [3]. …”
Section: Introductionmentioning
confidence: 99%